I have a couple of things.
CanSino is a private company. If I remember, it is publicly traded on the Hong Kong stock market. What we transferred to them, sir, was a cell line, which is a basic platform. It's actually their intellectual property in the vaccine, not ours. In that instance, our cell line was something that we have commercialized with many different people. We didn't have any concerns about the intellectual property because the cell line is a physical thing. The intellectual property risk, if there had been any, would have been around who owns the vaccine ID. In this instance, it was actually their ID and not ours.